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Abstract
Introduction: HLA-B*51 and HLA-B*52 are two close human leukocyte antigen (HLA) allele groups with minor
amino acid differences. However, they are associated with two different vasculitides (HLA-B*51 in Behçet’s disease
and HLA-B*52 in Takayasu’s arteritis (TAK)) and with major clinical and immunological differences. In this study, we
aimed to screen a large cohort of TAK patients from Turkey for the presence of HLA-B*51 and HLA-B*52 as
susceptibility and severity factors.
Methods: TAK patients (n = 330) followed at a total of 15 centers were included in the study. The mean age of
the patients was 37.8 years, and 86% were women. DNA samples from the patients and healthy controls (HC; n =
210) were isolated, and the presence of HLA-B*51 or HLA-B*52 was screened for by using PCR with sequence-
specific primers.
Results: We found a significant association of HLA-B*52 with TAK (20.9% vs HC = 6.7%, P = 0.000, OR = 3.7, 95% CI
= 2.02 to 6.77). The distribution of HLA-B*51 did not differ between TAK patients and HCs (22.7% vs 24.8%, OR =
0.9, 95% CI = 0.60 to 1.34). The presence of HLA-B*52 decreased in late-onset patients (> 40 years of age; 12.0%, P
= 0.024, OR = 0.43, 95% CI = 0.20 to 0.91). Patients with angiographic type I disease with limited aortic
involvement also had a lower presence of HLA-B*52 compared to those with all other disease subtypes (13.1% vs
26%, P = 0.005, OR = 0.43, 95% CI = 0.23 to 0.78).
Conclusions: In this study, the previously reported association of TAK with HLA-B*52 in other populations was
confirmed in patients from Turkey. The functional relevance of HLA-B*52 in TAK pathogenesis needs to be explored
further.
Introduction
Takayasu’s arteritis (TAK), also known as “pulseless dis-
ease,” is a chronic granulomatous panarteritis character-
ized by the involvement of large vessels, especially the
aorta and its major branches [1,2]. Although the etiology
of TAK is still unknown, infectious agents, genetic fac-
tors and autoimmunity are thought to play a major role
in its pathogenesis [3]. Cell-mediated autoimmunity has
been implicated in the physiopathology of vascular cell
injury in TAK. In addition to gδ T cells, natural killer
(NK) cells and macrophages, tissue specimens from the
aortas of TAK patients are infiltrated with T cells that
have a restricted T-cell repertoire, which is typical of
antigen-induced proliferation [4-6].
Evidences of genetic susceptibility to TAK have pre-
viously been demonstrated for SNPs of cytokine genes
such as IL-2, IL-6 and IL-12 and the NFKBIL1 promoter
region [7,8], but not with autoimmunity associated
genes such as PTPN22 [9] and PDCD1 [10]. Genes
encoding human leukocyte antigen (HLA) are highly
polymorphic, show remarkable ethnic and geographic
differences in allele and haplotype frequencies and are
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natural candidates for genetic susceptibility to immune
and inflammatory diseases. Although some associations
with class II alleles such as HLA-DRB*1301 have been
reported, studies from mainly East Asian countries have
demonstrated HLA-B*52 as the main risk factor in the
HLA region [11,12]. However, this association has not
been confirmed in North American and Arab popula-
tions [13,14].
HLA-B*51 and HLA-B*52 are two HLA-B allele groups
with only two amino acid differences [15]. However,
HLA-B*51 is associated with a phenotypically separate
vasculitis, namely, Behçet’s disease [16]. Previously, asso-
ciations of both major HLA-B subtypes HLA-B*51 and
HLA-B*52 with TAK have been shown only in an Indian
population [17]. On the basis of this background, we
screened patients with TAK in Turkey for the presence
of HLA-B*51 and HLA-B*52.
Materials and methods
The study was designed as a case-control study. We
enrolled 330 patients with TAK (42 men and 288
women, mean age 38.9 ± 12.2 years) of mixed ethnic
origin from Turkey. The patients were referred from 15
tertiary university and state hospital rheumatology cen-
ters in Turkey. Patients were classified according to the
1990 American College of Rheumatology criteria for
TAK [18]. According to the angiographic classification
scheme defined at the International Conference on
Takayasu’s Arteritis in Tokyo, 39.4% (n = 130) of the
patients had type I vessel involvement, 6.4% had type IIa
(n = 21), 2.7% had type IIb (n = 9), 3.9% had type III (n
= 13), 4.5% had type IV (n = 15) and 43% had type V (n
= 142) [19]. A surgical procedure was performed in
21.1% of the patients, with 11.6% done after immuno-
suppressive (IS) therapy. Patients with late-onset (> 40
years of age) disease was present in 23.8% of the
patients. Corticosteroid treatment was given to 95% of
the patients, standard first-line ISs (methotrexate, aza-
tioprine, leflunomide or cyclophosphamide) were admi-
nistered to 94.5% and second-line ISs (TNF antagonists)
were given to 3.5%.
To evaluate HLA-disease phenotype associations, our
study group proposed a consensus definition of “refrac-
tory disease” for TAK. Patients with “angiographic or
clinical progression despite treatment” or any of the fol-
lowing characteristics were accepted to have “refractory”
disease: corticosteroid dose > 7.5 mg/day after 6 months
of treatment, despite the administration of conventional
ISs (methotrexate, azatioprine, leflunomide or cyclopho-
sphamide); new surgery due to persistent disease activ-
ity; frequent attacks (more than three yearly); or death
associated with disease activity. On the basis of this defi-
nition, 27.4% (n = 114) of the patients with sufficient
follow-up for analysis had refractory disease. Eighteen
patients (5.9%) died during follow-up.
A total of 210 healthy blood donors (97 men and 113
women, mean age 32.2 ± 10.9 years) with the same
mixed ethnic origin from Turkey were recruited for par-
ticipation as healthy controls (HCs). All patients and
controls were enrolled with the approval of the Mar-
mara University Medical School Local Ethics Committee
and provided their informed consent.
Genotyping
For genotyping, cellular DNA was isolated from periph-
eral blood using standard procedures. For the determi-
nation of HLA-B*52 and HLA-B*51 alleles, DNA was
amplified using the forward primers HLA 192 and HLA
193, respectively, and reverse primer HLA 216 (for
both) for the specific product with another pair of pri-
mers was used as a control product [20]. PCR amplifica-
tion was carried out in NH4 buffer with 1.3 mM MgCl2,
0.2 μM deoxyribonucleotide triphosphate, 0.5 μM of
each primer, 60 ng of genomic DNA and 1 IU of Taq
polymerase. The cycling parameters were as follows: an
initial denaturation step of 2 minutes at 95°C; 5 cycles
of 20 seconds at 95°C, 60 seconds at 64°C and 20 sec-
onds at 72°C followed by 25 cycles of 20 seconds at 95°
C, 60 seconds at 63°C and 20 seconds at 72°C; and a
final extension step of 2 minutes at 72°C. Products were
run on 1.5% agarose gel stained with ethidium bromide.
Statistical analysis
HLA alleles in TAK patients were compared with those
of the HCs and within the patient group. The strength
of the association was expressed by the OR, and the sta-
tistical significance was examined by c2 test.
Results
We found a significant association of HLA-B*52 with
TAK (20.9% of patients (69 of 330) vs 6.7% of HCs (14
of 210), P = 0.000, OR = 3.7, 95% CI = 2.02 to 6.77).
The association of HLA-B*52 with TAK was noted in
women (21.5% vs 7.1%, P = 0.000, OR = 3.6, 95% CI =
1.66 to 7.79), but did not reach significance in men
(16.7% vs 6.2%, P = 0.063). The distribution of HLA-
B*51 did not differ between TAK patients and controls
(22.7% of patients (75 of 330) vs 24.8% of HCs (52 of
210), P = 0.3, OR = 0.9, 95% CI = 0.60 to 1.34).
When we investigated HLA-B*52 presence according
to the onset of disease, a decreased presence of HLA-
B*52 was observed in late-onset patients (> 40 years of
age) (early onset 24.2% vs late onset 12.0%, P = 0.024,
OR = 0.43, 95% CI = 0.20 to 0.91) (Table 1). We then
investigated whether the presence of HLA-B*52 affects
the disease phenotype. Although we observed that the
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frequency of HLA-B*52 was significantly higher in all
disease subtypes than in HCs, a lower presence of HLA-
B*52 was present in patients with type I disease (13.1%)
(P = 0.005, OR = 0.43, 95% CI = 0.24 to 0.78) compared
to all other types of vessel involvement (types IIa
through V, 26%). Although the finding did not reach
statistical significance, patients defined as having refrac-
tory disease also seemed to have a stronger association
with HLA-B*52 (refractory 27.4% vs nonrefractory
18.1%, P = 0.84, OR = 1.68, 95% CI = 0.97 to 2.93). No
association of surgery and IS drug requirement after
surgery with HLA-B*52 presence was present (surgery
HLA-B*52 13.6% vs 21.6%, P = 0.092, OR = 0.51, 95%
CI = 0.24 to 1.09; IS after surgery HLA-B*52 19.4% vs
21.6, P = 1.0). No association of HLA-B*51 presence was
observed with gender, age, disease phenotype, treatment
or any other clinical feature of TAK (Table 1).
Discussion
Researchers in various previous studies have demon-
strated a strong association of HLA-B*52 in TAK. Our
first study from Turkey, with a relatively large sample,
has confirmed this association. No association of HLA-
B*51 with TAK was present in this series.
The highest presence of HLA-B*52 in TAK was pre-
viously reported in a Japanese population (41%, RR =
2.2) [11]. In Japan, HLA-B*52 is also associated with
aortic insufficiency, ischemic heart disease and pulmon-
ary involvement [21]. We observed no association with
these clinical features in our series. However, the rou-
tine use of ISs in our patients might have affected our
results. Features of a more severe and refractory disease
are also associated with HLA-B*52 presence in Japan:
higher blood pressure, acute phase response and corti-
costeroid requirement [22,23]. Interestingly, we also
observed a mild association of HLA-B*52 with more
extensive aortic disease and refractoriness to treatment,
which might suggest an association of HLA-B*52 with a
more severe disease spectrum.
Studies from East Asian countries such as Korea,
Thailand and India confirmed a HLA-B*52 association
with TAK, though usually with a lower prevalence than
Japan (Thailand and Korea both 15%) [12,24]. The lower
presence of HLA-B*52 in patients with TAK might be
Table 1 Distribution of HLA-B*51 and HLA-B*52 allele groups in healthy controls and Takayasu’s arteritis patientsa
Characteristics n HLA-B*52+ (%) P OR (95% CI) HLA-B*51+ (%) P
HC 210 14 (6.7) 52 (24.8)
Men 97 6 (6.2) 23 (23.7)
Women 113 8 (7.1) 29 (25.7)
TAK 330 69 (20.9) 0.000 3.7 (2.02 to 6.77) 75 (22.7) 0.64
Men 42 7 (16.7) 0.063 12 (28.6) 0.53
Women 288 62 (21.5) 0.000 3.6 (1.66 to 7.79) 63 (21.9) 0.43
Age at onset
< 40 years 240 58 (24.2) 0.024 0.43 (0.20 to 0.91) 49 (20.4) 0.11
≤ 40 years 75 9 (12.0) 22 (29.3)
Angiographic subtypeb
Type I 130 17 (13.1) 0.005 0.43 (0.23 to 0.78) 28 (21.5) 0.78
Type Iia 21 8 (38.1) 6 (28.6)
Type Iib 9 3 (33.3) 2 (22.2)
Type III 13 5 (38.5) 3 (23.1)
Type IV 15 3 (20.0) 1 (6.7)
Type V 142 34 (23.9) 35 (24.6)
Surgery (all)
Present 66 9 (13.6) 0.092 0.51 (0.24 to 1.09) 13 (19.7) 0.62
Not present 246 58 (23.6) 57 (23.2)
Surgery after IS treatment
Present 36 7 (19.4) 1.0 9 (25) 0.67
Not present 273 59 (21.6) 60 (22.0)
Refractory disease
Refractory 114 31 (27.4) 0.084 1.68 (0.97 to 2.93) 20 (17.5) 0.12
Not refractory 193 35 (18.1) 49 (25.4)
aHC, healthy control; IS, immunosuppressive; TAK, Takayasu’s arteritis. Subgroup analysis was performed between groups with or without known clinical features.
bP vs other all other subtypes.
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associated with the lower prevalence in the background
HCs (HLA-B*52 in HCs in Japan 23%, in Thailand 2.3%
and in Turkey 6.7%). Association of HLA-B*52 with
TAK has also been reported in other ethnic groups,
such as Mexicans and Greeks [25,26]. Lack of associa-
tion in North America and Arab populations requires
confirmatory studies, as the number of samples has
been too low in these studies to draw any conclusions
[13,14].
Late-onset TAK (> 40 years of age) poses difficulties
in the differential diagnosis from giant cell arteritis
(GCA), and the two diseases are suggested to be a con-
tinuum with overlapping features [27]. In this context,
HLA-B*52 might be a specific genetic susceptibility
factor for classic early-onset TAK, as no association of
GCA with HLA-B*52 has been reported previously
[28].
Associations with other HLA genes in patients from
Korea (HLA-A*3001, HLA-DRB1*1502) and Mexico
(HLA-DRB1*1301) have also been reported; however,
they have not been confirmed in other populations
[29,30]. Although regions close to HLA-B, such as major
histocompatibility complex class I-related chain A, have
also been investigated for linkage disequilibrium in
Japan, no further association has been confirmed [31].
An association of HLA-B*3901 with TAK has also been
reported in studies conducted in Japan and Mexico
[32,33]. However, this association has not been con-
firmed in India, Greece or Korea [17,26,29]. We also
previously looked at HLA-B*39 in a subset of our popu-
lation and observed no association with TAK (2.9% vs.
3.6%) (unpublished observation, M. Bicakcigil, et al).
The lack of association of HLA-B*51 with TAK, a
granulomatous vasculitis, has important implications for
the pathogenesis of TAK. As HLA-B*51 (a very common
allele in Turkey) is associated only with Behçet’s disease,
an inflammatory disease involving the activation of both
innate and adaptive immunity, peptide-binding differ-
ences of HLA-B*51 and HLA-B*52 seem to predispose
patients to very different clinical phenotypes of vasculitis
[34]. Moreover, the association of HLA-B*52 seem to be
weaker in Turkish TAK patients compared to the HLA-
B*51-Behçet’s association, suggesting that other genetic
factors might have a larger effect on disease susceptibil-
ity in TAK [35].
Our study has some limitations. All patients were fol-
lowed in tertiary centers and may reflect a more severe
disease spectrum. As TAK is a rare disease, however, we
think that most patients suspected or diagnosed as hav-
ing TAK are referred to specialized centers in Turkey.
The gender ratio among TAK patients and HCs was not
well-matched in our study. Finally, we chose to study
only the HLA-B types previously associated with TAK,
and other alleles need to be studied as well.
Conclusion
We have confirmed the association of the HLA-B*52
allele with TAK in patients in Turkey. The negative
association with late-onset and milder forms of the dis-
ease needs to be confirmed in other populations.
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